Product Information
UCERIS 9 MG ER TABLET is a brand product labeled by Santarus Inc., priced at $57.1680 per EA under NDC 68012030930. Its NADAC has been published 524 times since Jul 23, 2014.
FDA first approved this application on Jan 14, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the budesonide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
9 mg/1
Manufacturer
Santarus Inc.NDC
68012030930
Classification
Brand
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/17/2025
Active Ingredients
BUDESONIDEApproval Type
New Drug (NDA)
FDA Application
NDA203634FDA Approved
1/14/2013
TE Code
AB
On Market Since
1/14/2013
Pharmacological Classes
Price Statistics
The NADAC for UCERIS 9 MG ER TABLET has been published 524 times since Jul 23, 2014, and over the history we have for it it has risen 33.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $57.1680 per EA |
|---|---|
| All-time high | $57.5303 (Apr 15, 2020) |
| All-time low | $42.7462 (Aug 20, 2014) |
| Median price | $57.1028 |
| Average price | $54.4812 |
| Largest weekly change | +10.0% (Mar 25, 2015) |
| Weeks tracked | 524 |
| Tracking since | Jul 23, 2014 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-0.1%
5Y
+0.1%
All
+33.3%
Last surveyed Oct 1, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 76% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Santarus Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
budesonide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of UCERIS 9 MG ER TABLET?
The current National Average Drug Acquisition Cost (NADAC) for UCERIS 9 MG ER TABLET, manufactured by Santarus Inc., is $57.1680 per EA (NDC 68012030930), effective Oct 1, 2025.
How has the price of UCERIS 9 MG ER TABLET changed over time?
Over the history we have for it, the NADAC for UCERIS 9 MG ER TABLET has risen 33.3%. It has been tracked across 524 weekly CMS publications since Jul 23, 2014.
What are the highest and lowest recorded NADAC prices for UCERIS 9 MG ER TABLET?
Since Jul 23, 2014, the NADAC for UCERIS 9 MG ER TABLET has ranged from a low of $42.7462 (Aug 20, 2014) to a high of $57.5303 (Apr 15, 2020), with a median of $57.1028 per EA.
Are there cheaper alternatives to UCERIS 9 MG ER TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BUDESONIDE ER 9 MG TABLET, is $13.6545 per EA — about 76% below UCERIS 9 MG ER TABLET.
Who manufactures UCERIS 9 MG ER TABLET?
UCERIS 9 MG ER TABLET (NDC 68012030930) is labeled by Santarus Inc., and CMS classifies it as a brand product.